Total raised
$281.8M
Last: PIPE 2025-10
Stage
Public
Founded
2009
Headcount
48
HQ
Tel Aviv-Yafo
Sector
Health Tech & Life Sciences
About
RedHill Biopharma is driven to develop extraordinary medicines for people to live extraordinary lives. RedHill applies innovation, focus and a collective mindset of delivering on its promises, to build a company at the forefront of gastrointestinal and infectious diseases management.
Its two FDA-approved drugs are promoted in the U.S. by a dedicated and experienced sales team: Talicia and Aemcolo.
RedHill has also built an exciting, advanced and largely de-risked R&D pipeline of proprietary late-stage clinical development drug candidates addressing major unmet medical needs.
Funding history · 11 rounds · $281.8M total
2025-10
PIPE
$4.0M
2024-04
PIPE
$1.3M
2024-01
PIPE
$8.0M
2023-04
PIPE
$6.0M
2022-05
PIPE
$15.0M
2021-11
PIPE
$10.0M
2020-02
Debt Financing
$115.0M
2019-10
PIPE
$36.0M
2014-01
PIPE
$11.7M
2012-12
PIPE
$6.5M
2010-11
Seed
$10.0M
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesHealthcarePatientsLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
inflammatory-diseasescrohn-s-diseasebiopharmaceuticaloral-drugsmedical-productsgastroenterologypharmaceuticalsoncologyhealthcare-providersorphan-drugpatientsinfectious-disease